Mergers & Acquisitions ·
Lantheus discloses Morgan Stanley valuation of $63.85 to $118.60 per share amid stockholder complaints over merger proxy
LNTHLantheus Holdings, Inc.
Lantheus Holdings filed an 8-K to disclose supplemental information regarding its proposed merger with Curium US Holdings LLC following the filing of three stockholder complaints alleging omissions in the definitive proxy statement concerning financial projections and Morgan Stanley's fairness opinion. To address these claims without admitting liability, Lantheus disclosed updated details from Morgan Stanley’s valuation analysis as of June 30, 2026. The discounted cash flow analysis yielded an implied value per share of $88.10 to $118.60, while the publicly traded companies analysis resulted in a range of $63.85 to $84.20. These valuations were based on 68.2 million fully diluted shares, $593 million in cash, and $575 million in convertible debt. The company also disclosed that Morgan Stanley held between 2% and 3% of Lantheus common stock and received fees of $5 million to $10 million from both Lantheus and CapVest affiliates over the prior two years. Lantheus Holdings, Inc. operates in the medical imaging industry, developing and commercializing radiopharmaceuticals for oncology and neurology.